Tenaya Therapeutics (TNYA) Depreciation & Amortization (CF) (2020 - 2026)

Tenaya Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 33.75% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $7.5 million (down 16.0% YoY), while the FY2025 annual figure was $8.4 million, changed 0.38% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.8 million, down from $1.8 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.7 million in Q1 2025, with the low at $966000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $2.1 million (2024), against an average of $2.0 million.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 179.76% in 2022, then tumbled 33.75% in 2026.
• Tenaya Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million in 2022, then increased by 3.02% to $2.2 million in 2023, then decreased by 4.22% to $2.1 million in 2024, then declined by 12.54% to $1.8 million in 2025, then declined by 3.5% to $1.8 million in 2026.
• Business Quant data shows TNYA's Depreciation & Amortization (CF) at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.9 million in Q3 2025.